Literature DB >> 25175631

Femoral pseudoaneurysms after percutaneous access.

Patrick A Stone1, John E Campbell2, Ali F AbuRahma2.   

Abstract

The femoral artery has been the primary percutaneous-based arterial access site for coronary artery catheterizations for more than three decades. Noncardiac percutaneous-based procedures have also been performed primarily with femoral access and have increased in number exponentially by vascular specialists in past decades. Groin complications are infrequent in incidence after femoral arterial access for cardiac and peripheral diagnostic and interventional cases, with groin hematomas and pseudoaneurysms being the most common. Until ultrasound-based treatment modalities became the mainstay of treatment, vascular surgeons were the primary specialty managing pseudoaneurysms, but now other specialties also manage these cases. This review outlines the clinical implications and current issues relevant to understanding the ideal treatment strategy for this common complication.
Copyright © 2014 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25175631     DOI: 10.1016/j.jvs.2014.07.035

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  21 in total

Review 1.  Pseudoaneurysms of the Peripheral Arteries.

Authors:  Jon C Henry; Randall W Franz
Journal:  Int J Angiol       Date:  2019-01-22

Review 2.  Hemostasis and nanotechnology.

Authors:  Patrick Hangge; Jonathan Stone; Hassan Albadawi; Yu Shrike Zhang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

3.  High-density electroanatomic mapping with grid catheter in pediatrics and congenital heart disease.

Authors:  Johannes C von Alvensleben; Amneet Sandhu; Shu Chang; D Martin Runciman; Melissa Wehrmann; D Wendy Tzou; Michal Schäfer; Kathryn K Collins
Journal:  J Interv Card Electrophysiol       Date:  2022-09-15       Impact factor: 1.759

4.  Ultrasound-Guided Thrombin Injection Is a Safe and Effective Treatment for Femoral Artery Pseudoaneurysm in the Morbidly Obese.

Authors:  Taehwan Yoo; Jean E Starr; Michael R Go; Patrick S Vaccaro; Bhagwan Satiani; Mounir J Haurani
Journal:  Vasc Endovascular Surg       Date:  2017-05-31       Impact factor: 1.089

5.  Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study.

Authors:  Jonathan Delf; Sanjeev Ramachandran; Syed Mustafa; Abdullah Saeed; Neghal Kandiyil
Journal:  Br J Radiol       Date:  2019-05-15       Impact factor: 3.039

6.  Complications of Cardiac Catheterization in Structural Heart Disease.

Authors:  Ko Eun Lee; Yeon Jeong Seo; Gi Beom Kim; Hyo Soon An; Young Hwan Song; Bo Sang Kwon; Eun Jung Bae; Chung Il Noh
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

7.  Resuscitative endovascular balloon occlusion of the aorta for uncontrolled haemorrahgic shock as an adjunct to haemostatic procedures in the acute care setting.

Authors:  Junya Tsurukiri; Itsurou Akamine; Takao Sato; Masatsugu Sakurai; Eitaro Okumura; Mariko Moriya; Hiroshi Yamanaka; Shoichi Ohta
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-02-09       Impact factor: 2.953

Review 8.  Multidetector CT of iatrogenic and self-inflicted vascular lesions and infections at the groin.

Authors:  Massimo Tonolini; Anna Maria Ierardi; Gianpaolo Carrafiello; Domenico Laganà
Journal:  Insights Imaging       Date:  2018-04-19

9.  Risk factors attributed to failure of ultrasound-guided compression for post-cardiac catheterization femoral artery pseudoaneurysms.

Authors:  Nawaf J Shatnawi; Nabil A Al-Zoubi; Jadallah Jarrah; Yousef Khader; Mowafeq Heis; Mamoon H Al-Omari
Journal:  SAGE Open Med       Date:  2019-04-16

10.  Access site pseudoaneurysms after endovascular intervention for peripheral arterial diseases.

Authors:  Ahmed Eleshra; Daehwan Kim; Hyung Sub Park; Taeseung Lee
Journal:  Ann Surg Treat Res       Date:  2019-05-29       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.